Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Anne B. Rossebø(Oslo University Hospital), Ronnie Willenheimer(Lund University), Philippe Brudi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kristian Wachtell(Rigshospitalet), Kurt Boman(Umeå University), John B. Chambers(St Thomas' Hospital), Christoph Nienaber(St. Michael's Hospital), Simon Ray, Kenneth Egstrup(Centre for Advanced Study), Terje Skjærpe(Norwegian University of Science and Technology), Eva Gerdts(University of Bergen), Christa Gohlke-Bärwolf(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Terje R. Pedersen(University of Oslo), William Malbecq(MSD (Belgium)), Ingar Holme(Oslo University Hospital), Y. Antero Kesäniemi(University of Oulu)
Cited by 1,622
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases
|European Heart Journal|2014|4.4k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice
|Journal of the American Society of Echocardiography|2009|2.1k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k